Crinetics Pharmaceuticals Inc.
Somatostatin agonists to treat acromegaly
This article was originally published in Start Up
Executive Summary
The founders of Crinetics Pharmaceuticals Inc. aim to treat endocrine-related diseases and cancers with novel molecules that target peptide hormone receptors. It has been working intensively to apply the concept of biased agonism to the large and popular class of drug targets known as G-protein coupled receptors; it will initially seek to develop a treatment for acromegaly.
You may also be interested in...
Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing
Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.